NVN Liquidation Inc (NOVNQ)
0.0008
0.00 (0.00%)
USD |
OTCM |
Apr 26, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0224M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -99.94% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 100.00% |
Profile
| NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy. |
| URL | https://www.novan.com |
| Investor Relations URL | N/A |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | May. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy. |
| URL | https://www.novan.com |
| Investor Relations URL | N/A |
| HQ State/Province | North Carolina |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | May. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |